Naphthalene Diimide Compounds with Mixed Basicity Side Chains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved anti-cancer agents with enhanced G-quadruplex binding ability and efficacy, as existing naphthalene diimide derivatives may have limitations in cellular uptake and tumor distribution while maintaining quadruplex interaction.
Innovation Solution
Development of tetra-substituted naphthalene diimide compounds with a combination of N-methyl-piperazine and morpholino groups on their side-arms, which modulate the basicity to improve pharmacological properties and selectivity for quadruplex DNA over duplex DNA, allowing for better cancer treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naphthalene diimide compounds with four positively-charged N-methyl-piperazine groups are used, then G-quadruplex binding ability and telomerase inhibition are improved, but cellular uptake and tumor distribution are compromised
Solution Approach 1:
The patent modifies the basicity parameter of the side chains by replacing some N-methyl-piperazine groups (highly basic) with morpholino groups (less basic). This parameter change reduces the overall positive charge density while maintaining sufficient G-quadruplex binding ability, thereby improving cellular uptake and tumor distribution without compromising the primary function.
Solution Approach 2:
The patent creates composite side chain structures combining different basicity characteristics (N-methyl-piperazine and morpholino groups) within the same molecule. This composite approach allows the molecule to simultaneously achieve adequate quadruplex interaction through residual basic groups while improving pharmacological properties through the less basic morpholino groups.
2Ease of manufacture
If compounds with two N-methylpiperazine side chains are used, then synthesis complexity is reduced, but G-quadruplex binding ability and anti-cancer effects are insufficient
Solution Approach 1:
The patent applies local quality by having different side chains with different basicity characteristics at different positions of the naphthalene diimide core. Specifically, two N-methyl-piperazine groups provide strong local basicity for quadruplex binding, while two morpholino groups provide moderate basicity, creating a balanced overall profile that maintains synthesis simplicity while achieving adequate binding ability.
3Reliability
If the basicity of side chains is increased to improve quadruplex interaction, then G-quadruplex binding is enhanced, but selectivity for quadruplex over duplex DNA is reduced
Solution Approach 1:
The patent optimizes the basicity parameter by using a mix of highly basic (N-methyl-piperazine) and moderately basic (morpholino) groups. This balanced approach provides sufficient electrostatic interaction for quadruplex binding while avoiding excessive basicity that would cause non-specific binding to duplex DNA, thereby improving selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified compounds demonstrate superior selectivity and anti-proliferative activity in cancer cell lines, inducing cellular senescence and DNA damage responses, thereby effectively inhibiting cancer cell growth without compromising quadruplex interaction.
Implementation Method 1
small molecules can sequester the single-stranded overhang of human telomeric DNA into higher-order quadruplex DNA structures... the resulting stabilized quadruplex-ligand complexes can interfere with the processivity of the reverse transcriptase telomerase enzyme complex
Implementation Method 2
Quadruplex targeting has also been shown to provoke a DNA damage response in cells
Data Source
AI summary
The invention relates to novel compounds which are naphthalene diimides of general formula (I):The compounds are used in therapy, particularly in cancer treatment.